Payment overview · 2025
General Payments
$194.89
10 reported records · 9 companies
Healthcare provider profile · identity verified
Richard Lee Carpenter, MD
Allopathic & Osteopathic Physicians|Family Medicine · ELLOREE, SC · NPI 1376600486
Verified facts
What the public records show
CMS Open Payments records show Richard Lee Carpenter, MD received $194.89 in general payments during 2025 across 10 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.95 | 22.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.78 | 15.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.08 | 12.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.21 | 9.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.74 | 8.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.65 | 8.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.48 | 8.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.40 | 7.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.60 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $194.89 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.95 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.78 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 152 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
231 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
152 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 975 | 209 |
| Atorvastatin Calcium | Atorvastatin Calcium | 953 | 205 |
| Levothyroxine Sodium | Levothyroxine Sodium | 622 | 139 |
| Pantoprazole Sodium | Pantoprazole Sodium | 621 | 139 |
| Gabapentin | Gabapentin | 564 | 137 |
| Meloxicam | Meloxicam | 493 | 143 |
| Pravastatin Sodium | Pravastatin Sodium | 436 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 433 | 104 |
| Losartan Potassium | Losartan Potassium | 414 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 402 | 107 |
| Alprazolam | Alprazolam | 375 | 58 |
| Furosemide | Furosemide | 375 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 372 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 366 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 355 | 86 |
| Lisinopril | Lisinopril | 355 | 88 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 339 | 85 |
| Omeprazole | Omeprazole | 335 | 74 |
| Prednisone | Prednisone | 315 | 195 |
| Metformin Hcl Er | Metformin Hcl | 308 | 80 |
| Lorazepam | Lorazepam | 302 | 68 |
| Famotidine | Famotidine | 297 | 78 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 281 | 63 |
| Metformin Hcl | Metformin Hcl | 270 | 60 |
| Mounjaro | Tirzepatide | 249 | 36 |
| Montelukast Sodium | Montelukast Sodium | 235 | 60 |
| Sertraline Hcl | Sertraline Hcl | 234 | 56 |
| Trazodone Hcl | Trazodone Hcl | 233 | 60 |
| Farxiga | Dapagliflozin Propanediol | 231 | 34 |
| Tramadol Hcl | Tramadol Hcl | 229 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 219 | 49 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 191 | 46 |
| Allopurinol | Allopurinol | 186 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 186 | 140 |
| Potassium Chloride | Potassium Chloride | 185 | 39 |
| Carvedilol | Carvedilol | 181 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 181 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 178 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 176 | 35 |
| Eliquis | Apixaban | 174 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 173 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 169 | 35 |
| Doxazosin Mesylate | Doxazosin Mesylate | 166 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 163 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 58 |
| Tresiba Flextouch U-100 | Insulin Degludec | 153 | 26 |
| Jardiance | Empagliflozin | 152 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 142 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 140 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 133 | 25 |
| Valsartan | Valsartan | 133 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 27 |
| Simvastatin | Simvastatin | 127 | 37 |
| Clonazepam | Clonazepam | 115 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 115 | 77 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 114 | 13 |
| Irbesartan | Irbesartan | 112 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 41 |
| Mirtazapine | Mirtazapine | 111 | 30 |
| Mupirocin | Mupirocin | 109 | 64 |
| Benazepril Hcl | Benazepril Hcl | 108 | 23 |
| Levetiracetam | Levetiracetam | 106 | 17 |
| Diazepam | Diazepam | 104 | 30 |
| Pregabalin | Pregabalin | 104 | 17 |
| Donepezil Hcl | Donepezil Hcl | 102 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 32 |
| Cephalexin | Cephalexin | 97 | 87 |
| Linzess | Linaclotide | 97 | 15 |
| Glimepiride | Glimepiride | 96 | 22 |
| Atenolol | Atenolol | 94 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 94 | 77 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 92 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 70 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 32 |
| Celecoxib | Celecoxib | 84 | 23 |
| Clonidine Hcl | Clonidine Hcl | 84 | 19 |
| Spironolactone | Spironolactone | 82 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 76 | 23 |
| Solifenacin Succinate | Solifenacin Succinate | 74 | 20 |
| Meclizine Hcl | Meclizine Hcl | 73 | 36 |
| Januvia | Sitagliptin Phosphate | 71 | 18 |
| Trulicity | Dulaglutide | 70 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 16 |
| Ozempic | Semaglutide | 68 | 12 |
| Xarelto | Rivaroxaban | 66 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 64 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 64 | 15 |
| Ezetimibe | Ezetimibe | 64 | 16 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 64 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 31 |
| Fluconazole | Fluconazole | 60 | 34 |
| Topiramate | Topiramate | 60 | 12 |
| Azithromycin | Azithromycin | 58 | 46 |
| Verapamil Er | Verapamil Hcl | 56 | suppressed |
| Ibuprofen | Ibuprofen | 55 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 15 |
| Baclofen | Baclofen | 52 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 16 |
| Finasteride | Finasteride | 50 | 13 |
| Ketoconazole | Ketoconazole | 49 | 28 |
| Promethazine Hcl | Promethazine Hcl | 49 | suppressed |
| Colchicine | Colchicine | 48 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 11 |
| Amoxicillin | Amoxicillin | 43 | 39 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 42 | 27 |
| Azelastine Hcl | Azelastine Hcl | 41 | 17 |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Estradiol | Estradiol | 40 | 13 |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Fentanyl | Fentanyl | 39 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | 12 |
| Sucralfate | Sucralfate | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | suppressed |
| Turqoz | Norgestrel-Ethinyl Estradiol | 36 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Indomethacin | Indomethacin | 33 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 23 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 16 |
| Telmisartan | Telmisartan | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Cilostazol | Cilostazol | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Cryselle | Norgestrel-Ethinyl Estradiol | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | 12 |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Tresiba | Insulin Degludec | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $194.89 · 10 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, CAPLYTA, CAPVAXIVE, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Ozempic, REXULTI, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error